Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931430 | 0.87 | CCR2 (0.62) | CCR2 | |
| SCHEMBL15227592 | 0.80 | CCR2 (0.74) | CCR2 | |
| SCHEMBL16735493 | 0.79 | CCR2 (0.54) | CCR2 | |
| SCHEMBL9967994 | 0.77 | CCR2 (0.73) | CCR2 | |
| SCHEMBL9930821 | 0.77 | CCR2 (0.69) | CCR2 | |
| SCHEMBL9930773 | 0.76 | CCR2 (0.75) | CCR2 | |
| SCHEMBL9933274 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9931533 | 0.76 | CCR2 (0.75) | CCR2 | |
| SCHEMBL18672576 | 0.76 | CCR2 (0.75) | CCR2 | |
| SCHEMBL9931170 | 0.76 | CCR2 (0.74) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |